Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia

Oncologist

Volumn 12, Issue 4, 2007, Pages 362-365

  Lappin, Terence R ^a   Maxwell, A Peter ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG HALF LIFE; DRUG PROTEIN BINDING; HEAD AND NECK CANCER; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG EMBOLISM; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANEMIA; CLINICAL TRIALS; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; NEOPLASMS; SAFETY; SURVIVAL ANALYSIS;

EID: 34247857543     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-4-362     Document Type: Note

References (25)

1. U.S. Food and Drug Administration. Information for Healthcare Professionals. Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. FDA Alert, February 16, 2007. Available at http://www.fda.gov/cder/drug/InfoSheets/HCP/ RHE2007HCP.htm. Accessed March 21, 2007.
2. Danish Head and Neck Cancer Group. Interim analysis of DAHANCA 10, December 1, 2006. Available at http://frejacms.au.dk/dahanca/get_media_ file.php?mediaid=125. Accessed March 21, 2007.
3. F. Hoffmann-La Roche Limited. Recruitment Temporarily Suspended Into C.E.R.A. Phase II Oncology Trial. Roche Media News, February 23, 2007. Available at http://www.roche.com/med-cor-2007-02-23c. Accessed March 21, 2007.
4. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small cell lung cancer and disease-related anemia. J Clin Oncol 2007;25:1027-1032.
5. Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego: Erythropoietin has multiple actions. STEM CELLS 2002;20:485-492.
6. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
7. Witzig TE, Silberstein PT, Loprinzi CL et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients with cancer receiving chemotherapy. J Clin Oncol 2005;23:2606-2617.
8. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16(suppl 3):3-13.
9. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1225-1260.
10. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4: 459-460.
11. Steensma DP, Loprinzi CL. Erythropoietin use in cancer patients: A matter of life and death? J Clin Oncol 2005;23:5865-5868.
12. National Comprehensive Cancer Network. Cancer- and Treatment-Related Anemia, V.2.2007. Available at http://www.nccn.org/professionals/ physician_gls/PDF/anemia.pdf. Accessed March 21, 2007.
13. Bohlius J, Wilson J, Seidenfeld J et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;3:CD00 3407.
14. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714.
15. Anagnostou A, Lee ES, Kessimian N et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 1990;87:5978-5982.
16. Anagnostou A, Liu Z, Steiner M et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994;9:3974-3978.
17. Brown WM, Maxwell P, Graham AN et al. Erythropoietin receptor expression in non-small cell lung carcinoma: A question of antibody specificity. STEM CELLS 2007;25:718-722.
18. Elliott S, Busse L, Bass MB et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107:1892-1895.
19. Maxwell AP. Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure. Kidney Int 2002;62:720-729.
20. Elliott S, Lorenzini T, Asher S et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21:414-421.
21. Dunlop EA, Percy MJ, Boland MP et al. Induction of signalling in nonerythroid cells by pharmacological levels of erythropoietin. Neurodegener Dis 2006;3:94-100.
22. Dunlop EA, Maxwell AP, Lappin TR. Impaired downregulation following erythropoietin receptor activation in non-small cell lung carcinoma. STEM CELLS 2007;25:380-384.
23. Singh AK, Szczech L, Tang KL et al.; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-2098.
24. Drueke TB, Locatelli F, Clyne N et al.; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.
25. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1988;339:584-590.